clinical trial · NCT07142980
A Phase I Study of HRS-7172 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
Jiangsu HengRui Medicine Co., Ltd.·phase1·recruiting·n = 120
Advanced Solid Tumors Harboring RAS Mutations or AmplificationsHRS-7172 Tablets
brief summary
This is a phase I study of HRS-7172 to evaluate safety, tolerability and pharmacokinetics in participants with advanced solid tumors harboring RAS mutations or amplifications.
started
Sep 12, 2025
primary completion
Dec 1, 2028
completion
Dec 1, 2028
last updated
Nov 17, 2025
official title
A Phase I Study of HRS-7172 Evaluating Safety, Tolerability and Pharmacokinetics in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol